No Data
No Data
Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment
Chemomab Therapeutics Reports Promising Phase 2 SPRING Trial Data for Nebokitug, Showing Significant Improvements in Biomarkers for Primary Sclerosing Cholangitis and Other Fibro-Inflammatory Diseases
Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer
Press Release: Chemomab Announces New Medical and Clinical Appointments
Chemomab Therapeutics | 20-F: FY2024 Annual Report
Maxim Group Maintains Chemomab Therapeutics(CMMB.US) With Buy Rating, Maintains Target Price $7
71307633 : Why was the information taken back again?
Jaguar8 OP 71307633 : huh???